Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on Using Elotuzumab After Initial Therapy for Multiple Myeloma

Posted: Tuesday, July 2, 2019

For patients with biochemical disease progression after initial therapy for myeloma, would you consider combination therapy with a monoclonal antibody such as elotuzumab?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.